<code id='FBCF378DA8'></code><style id='FBCF378DA8'></style>
    • <acronym id='FBCF378DA8'></acronym>
      <center id='FBCF378DA8'><center id='FBCF378DA8'><tfoot id='FBCF378DA8'></tfoot></center><abbr id='FBCF378DA8'><dir id='FBCF378DA8'><tfoot id='FBCF378DA8'></tfoot><noframes id='FBCF378DA8'>

    • <optgroup id='FBCF378DA8'><strike id='FBCF378DA8'><sup id='FBCF378DA8'></sup></strike><code id='FBCF378DA8'></code></optgroup>
        1. <b id='FBCF378DA8'><label id='FBCF378DA8'><select id='FBCF378DA8'><dt id='FBCF378DA8'><span id='FBCF378DA8'></span></dt></select></label></b><u id='FBCF378DA8'></u>
          <i id='FBCF378DA8'><strike id='FBCF378DA8'><tt id='FBCF378DA8'><pre id='FBCF378DA8'></pre></tt></strike></i>

          Home / hotspot / hotspot

          hotspot


          hotspot

          author:explore    Page View:79732
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In